Technology

Webinar Date/Time: Thursday, October 3, 2024 at 2pm EDT|11am PDT|7pm BST|8pm CEST

Webinar Date/Time: Wednesday, September 25th, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Achieving better outcomes for patients and advancing the fields of nuclear medicine and oncology are not just about adopting new technologies, but also about embracing a profound change in how care is delivered.

The technology has the potential to be implemented across multiple aspects of the industry.

A Harvard Business School Healthcare Alumni Association Q&A with Kevin Werbach, Professor of Legal Studies and Business Ethics at the Wharton School.

Culjat discusses FDA’s new draft framework on PDURS.

How drugmakers can reap value from using generative AI in their market-entry strategies and decision-making, including mitigating launch challenges and enhancing the customer conversation.

It’s time to see where artificial intelligence is genuinely being utilized in pharma.

Webinar Date/Time: Thu, Sep 12, 2024 11:00 AM EDT

The region is moving to the forefront in integrating therapeutic innovation.

How interoperability and clean data can harness the power of big data in pharma.

PicnicHealth’s CEO discusses how AI is making data more useful to the life sciences industry.

New technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.

The lead transformation evangelist at Celonis discusses how digital twins are becoming more prominent in the pharma industry.

The AI-powered feature will provide detailed nutritional information based on photos of food taken by users.

Webinar Date/Time: Wed, Aug 28, 2024 11:00 AM EDT

Webinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT

EVERSANA’s senior vice president of innovation discusses how the technology has been implemented in various areas of the pharmaceutical industry.

The AscellaHealth CEO discusses how new technologies are increasing the options in patient care.

Dr. Varshney discusses how AI is being used to sort data and discover new molecules and indications for existing drugs.

Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.

How pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.

The CTO of Authenticx discusses preventing bias from becoming part of AI models.

Craig Tooman, CEO of Silence Therapeutics, on steering through the rough biotech funding and investment waters post-pandemic—and how a retooled organizational approach has the company in a stronger position today in the growing field of gene silencing through siRNA drugs.

BioXcel’s VP of AI drug discovery discusses how use of the technology has advanced in the past year.

Both systems are over-the-counter products that provide continuous glucose monitoring.

How AI Can Improve Engagement with Healthcare Professionals (HCPs).

The CEO of AION Labs discusses both the new ways that AI is being implemented in drug development and why Israel is becoming the center of AI development in the pharma industry.

The platform will use AI technology to provide pharmacists with more tools.

A greater shift from paper records and physical assets is achievable.